FATE vs HAL · rev $13.6M vs P/E 9.3, $19.05B cap
Fate Therapeutics Inc (FATE) versus Halliburton Company (HAL) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
HAL does not have a complete income-statement cache yet.
FATE currently screens at market cap $331.0M. HAL currently screens at market cap $19.05B and trailing P/E 9.3.
Not investment advice. Open the FATE and HAL stock pages for the full models.
Not investment advice.